Abstract: Objective To investigate the distribution of HBV genotypes and drug-resistant mutations in patients with chronic hepatitis B（CHB）. Methods 240 patients with CHB receiving monotherapy or swift from one to another of nuleos（t）ide analogues（NAs） for at least three months were recruited in this study,and the drug resistance mutation was assayed by sequencing reverse transcription area and the HBV genotypes were detected by sequencing HBV S gene. Results The resistant mutation rate in 35 patients treated by lamivudine was 40.0% with the resistant mutation sites of rtL80I/V,rtVl73L,rtLl80M,rtM204V/I,and rtV207I;the resistant mutation rate in 23 patients receiving adefovir was 47.8% with the mutation sites of rtAl81T/V,rtS213T/N, rtV214A,rtQ215S/H/P,rtl233V,rtN236T,rtP237H,rtN/H238A/K/D/S;the mutation rate in 70 receiving entecavir was 14.3% with the mutation sites of rtM204I;the resistant mutation rate in 12 patients receiving telbivudine 41.7% with the mutation sites of rtI169T,rtL180M,rtT184G/S/A/I/L/F,rtS202I/G,rtM204V and rtM250V/I/L;the resistance mutation rate in 100 patients with combination or swift therapy was 51.0% with the mutation sites of rtA194T;out of 240 patients with CHB,21（8.8%） were with type B,216（90.0%） were with type C,and 3 （1.2%） were with type D hepatitis B viral infection;out of the 91 patients with drug resistance mutations,6 （6.6%） were with type B,83（91.2%） were with type C,and 2（2.2%） were with type D infection;multidrug resistance mutations occurred in 2 （33.3%） of 6 patients with type B and 15（18.1%） of 83 type C infection. Conclusion Surveillance of HBV genotypes and resistance mutations in patients with CHB receiving NAs therapy might help improve the clinical response.

Key words: Hepatitis B, Nuleos（t）ide analogues, HBV genotypes, Drug resistance mutations